MCID: BRN101
MIFTS: 35

Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Categories: Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

MalaCards integrated aliases for Bronchiolitis Obliterans with Obstructive Pulmonary Disease:

Name: Bronchiolitis Obliterans with Obstructive Pulmonary Disease 58
Constrictive Bronchiolitis 58 71
Bronchiolitis Obliterans Organizing Pneumonia 71
Obliterative Bronchiolitis 58
Bronchiolitis Obliterans 71

Characteristics:


Age Of Onset:

All ages 58

Age Of Death:

any age 58

Classifications:

Orphanet: 58  
Rare respiratory diseases


External Ids:

ICD10 via Orphanet 32 J44.8
UMLS via Orphanet 72 C0006272 C2350875
Orphanet 58 ORPHA1303
UMLS 71 C0006272 C0242770 C2350875

Summaries for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Orphanet: 58 A rare lung disorder that is mainly associated with chronic allograft dysfunction after lung transplantation and that is characterized by inflammation and fibrosis of bronchiolar walls that reduce the diameter of the bronchioles and result in progressive and irreversible airflow obstruction.

MalaCards based summary: Bronchiolitis Obliterans with Obstructive Pulmonary Disease, also known as constrictive bronchiolitis, is related to bronchiolitis obliterans and cryptogenic organizing pneumonia. The drugs Salbutamol and Tiotropium have been mentioned in the context of this disorder. Affiliated tissues include lung, bone marrow and bone, and related phenotypes are dyspnea and hypoxemia

Related Diseases for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Diseases related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 bronchiolitis obliterans 11.6
2 cryptogenic organizing pneumonia 11.3
3 bronchiolitis 11.2
4 human cytomegalovirus infection 10.5
5 lung disease 10.5
6 bronchiectasis 10.4
7 respiratory failure 10.4
8 graft-versus-host disease 10.4
9 chronic graft versus host disease 10.4
10 pulmonary hypertension 10.3
11 vascular disease 10.3
12 bronchitis 10.3
13 paraneoplastic pemphigus 10.3
14 pneumonia 10.2
15 oral submucous fibrosis 10.2
16 extrinsic allergic alveolitis 10.2
17 hypereosinophilic syndrome 10.2
18 gastroesophageal reflux 10.1
19 ige responsiveness, atopic 10.1
20 neutrophilia, hereditary 10.1
21 pneumothorax, primary spontaneous 10.1
22 interstitial lung disease 2 10.1
23 pulmonary hypertension, primary, 1 10.1
24 rheumatoid arthritis 10.1
25 panbronchiolitis, diffuse 10.1
26 hyperlucent lung 10.1
27 pneumothorax 10.1
28 connective tissue disease 10.1
29 arthritis 10.1
30 lymphoma, hodgkin, classic 10.1
31 autoimmune disease 10.0
32 carcinoid tumors, intestinal 10.0
33 leukocyte adhesion deficiency, type i 10.0
34 parkinson disease, late-onset 10.0
35 pemphigus vulgaris, familial 10.0
36 down syndrome 10.0
37 williams-campbell syndrome 10.0
38 cystic fibrosis 10.0
39 goodpasture syndrome 10.0
40 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
41 sjogren syndrome 10.0
42 fanconi anemia, complementation group e 10.0
43 lymphangioleiomyomatosis 10.0
44 pulmonary disease, chronic obstructive 10.0
45 hypereosinophilic syndrome, idiopathic 10.0
46 severe cutaneous adverse reaction 10.0
47 aspergillosis 10.0
48 myelodysplastic syndrome 10.0
49 kartagener syndrome 10.0
50 aspiration pneumonia 10.0

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease:



Diseases related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Symptoms & Phenotypes for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Human phenotypes related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease:

58 30 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dyspnea 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002094
2 hypoxemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012418
3 bronchiolitis obliterans 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011946
4 reduced fev1/fvc ratio 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0030877
5 reduced forced vital capacity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0032341
6 reduced forced expiratory volume in one second 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0032342
7 decreased forced expiratory flow 25-75% 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0032359
8 pneumonia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002090
9 nonproductive cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0031246
10 decreased dlco 58 30 Frequent (33%) Frequent (79-30%)
HP:0045051
11 autoimmunity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002960
12 bronchiectasis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002110
13 ground-glass opacification 30 Very rare (1%) HP:0025179
14 cough 58 Very frequent (99-80%)
15 respiratory tract infection 58 Frequent (79-30%)
16 obstructive lung disease 58 Very frequent (99-80%)
17 ground-glass opacification on pulmonary hrct 58 Very rare (<4-1%)

Drugs & Therapeutics for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Drugs for Bronchiolitis Obliterans with Obstructive Pulmonary Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Salbutamol Approved, Vet_approved Phase 4 18559-94-9 2083
2
Tiotropium Approved Phase 4 136310-93-5, 186691-13-4 3086655 5487427 5487426
3
Aztreonam Approved Phase 4 78110-38-0 5742832
4
Azithromycin Approved Phase 4 83905-01-5 447043
5
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
6
Erythromycin Approved, Investigational, Vet_approved Phase 4 55-31-2, 114-07-8 12560
7
Dimercaprol Approved Phase 4 59-52-9 3080
8
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
9
D-Lysine Approved, Experimental, Nutraceutical Phase 4 923-27-3, 56-87-1 57449 5962
10 Anti-Infective Agents Phase 4
11 Tocolytic Agents Phase 4
12 Parasympatholytics Phase 4
13 Cholinergic Antagonists Phase 4
14 Cholinergic Agents Phase 4
15 Bromides Phase 4
16 Micronutrients Phase 4
17 Calciferol Phase 4
18 Vitamins Phase 4
19 Trace Elements Phase 4
20 Olive Phase 4
21 Anti-Bacterial Agents Phase 4
22 Gastrointestinal Agents Phase 4
23 Erythromycin stearate Phase 4
24 Erythromycin Ethylsuccinate Phase 4
25 Erythromycin Estolate Phase 4
26
Pirfenidone Approved, Investigational Phase 2, Phase 3 53179-13-8 40632
27
Basiliximab Approved, Investigational Phase 3 179045-86-4
28
Mycophenolic acid Approved, Investigational Phase 3 24280-93-1 446541
29
Clarithromycin Approved Phase 3 81103-11-9 84029
30
Nintedanib Approved Phase 3 656247-17-5 135423438 9809715
31
Azathioprine Approved Phase 3 446-86-6 2265
32
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643
33
Fluticasone Approved, Experimental Phase 3 90566-53-3 4659387 5311101
34
Methoxsalen Approved Phase 3 298-81-7 4114
35
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
36
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
37 Analgesics, Non-Narcotic Phase 2, Phase 3
38 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
39 Analgesics Phase 2, Phase 3
40 Cytochrome P-450 Enzyme Inhibitors Phase 3
41 Cytochrome P-450 CYP3A Inhibitors Phase 3
42 Bronchodilator Agents Phase 3
43 Respiratory System Agents Phase 3
44 Anti-Asthmatic Agents Phase 3
45 Protein Kinase Inhibitors Phase 3
46 Hormones Phase 3
47 Hormone Antagonists Phase 3
48 Xhance Phase 3
49 glucocorticoids Phase 3
50 Sympathomimetics Phase 3

Interventional clinical trials:

(show top 50) (show all 89)
# Name Status NCT ID Phase Drugs
1 Acute Bronchodilator Responsiveness in Obliterative Bronchiolitis (OB) Following Hematopoietic Stem Cell Transplantation Completed NCT01112241 Phase 4 albuterol plus tiotropium
2 A Randomized, Double Blind, Placebo Controlled Trial With Montelukast to Treat Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01211509 Phase 4 Montelukast
3 A Randomized Double Blind Placebo Controlled Trial With Vitamin D to Prevent Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01212406 Phase 4 Vitamin D
4 Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
5 Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans Completed NCT00367419 Phase 4 Erythromycin
6 Double-blind Placebo Trial to Determine the Efficacy and Safety of Treatment With Azithromycin for 6 Months in Patients With Post-infectious Bronchiolitis Obliterans Completed NCT05299567 Phase 4 Azithromycin
7 Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation. Completed NCT01009619 Phase 4 Azithromycin;Placebo
8 Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01959100 Phase 3 Azithromycin;Placebo
9 A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
10 A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-3 in Lung Transplant Recipients Completed NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
11 A Randomized, Double Blind, Placebo Controlled Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans Syndrome in Bilateral Lung and Single Lung Transplant Patients Completed NCT00188825 Phase 3 basiliximab
12 Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
13 Phase III, Randomized, Double Blind Study of Low Dose Long Term Clarithromycin Versus Placebo in Treatment of Chronic Pulmonary Lesions Due to Sulfur Mustard Completed NCT00381147 Phase 3 Clarithromycin
14 A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant Recruiting NCT03656926 Phase 3 Liposomal Cyclosporine A;Standard of Care
15 A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 0p-1-2 Recruiting NCT03283007 Phase 3 Nintedanib;Placebo
16 A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant Recruiting NCT03657342 Phase 3 Liposomal Cyclosporine A;standard of care
17 Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation Recruiting NCT04655508 Phase 3 Seretide;Placebo
18 Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts Active, not recruiting NCT02181257 Phase 3
19 A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant Enrolling by invitation NCT04039347 Phase 3 Liposomal Cyclosporine A 5 mg;Liposomal Cyclosporine A 10 mg
20 A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
21 A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy Terminated NCT01439958 Phase 3 Inhalation
22 Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
23 Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
24 Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome Completed NCT01287078 Phase 2 Cyclosporine Inhalation Solution
25 Open-labeled Trial to Evaluate the Therapeutic Effects of Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans After Allogeneic Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
26 Multi-Institutional Prospective Phase II Study of Montelukast for the Treatment of Bronchiolitis Obliterans Following Allogeneic or Autologous Stem Cell Transplantation in Children and Adults Completed NCT00656058 Phase 2 Singulair (Montelukast Sodium)
27 Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
28 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed NCT01273207 Phase 2 Cyclosporine Inhalation Solution (CIS)
29 recipientsProspective Evaluation of the Efficacy of Budesonide/Formoterol (Symbicort®) in Bronchiolitis Obliterans in Allogeneic Haematopoietic Stem Cell Transplantation (AHSCT) Recipients Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
30 A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
31 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
32 Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study Completed NCT00141726 Phase 2 Etanercept
33 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation (HSCT)- a Multicentre Phase II Trial Recruiting NCT03805477 Phase 2 Nintedanib
34 A Phase 1b/2 Study of Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 MPH966
35 Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT05413356 Phase 2 Ruxolitinib
36 Imaging and Understanding Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation With Hyperpolarized 129Xenon MR Lung Imaging Recruiting NCT03603899 Phase 1, Phase 2 Hp 129Xenon
37 A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Recruiting NCT03674047 Phase 2 ruxolitinib
38 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110) Recruiting NCT04640025 Phase 2 itacitinib
39 Ruxolitinib for Early Lung Dysfunction After HSCT: a Phase II Study Recruiting NCT04908735 Phase 2 Ruxolitinib
40 A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT04107675 Phase 2 Liposomal Cyclosporine A;Liposomal Placebo
41 An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Active, not recruiting NCT03978637 Phase 1, Phase 2 Itacitinib
42 Does Increasing Immunosuppression Prevent Transplant-associated Lung-disease Triggered by Viral Respiratory Tract Infection Following Allogeneic Stem Cell Transplant? A Pilot Study Terminated NCT01432080 Phase 2 Prednisone;Azithromycin;Montelukast;Symbicort
43 A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Terminated NCT01163786 Phase 2 Bortezomib
44 Prospective Study for Transplant Optimization Using Functional Imaging (TROFI) Terminated NCT02488304 Phase 2
45 A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation Completed NCT01175655 Phase 1
46 The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation Completed NCT03315741 Phase 1 Pirfenidone 267 MG [Esbriet]
47 A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells to Induce Remission in Lung Transplant Patients Experiencing Treatment-refractory Moderate to Severe Lung Rejection Completed NCT02181712 Phase 1
48 A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplant (HCT) Recruiting NCT04239989 Phase 1 Itacitinib;Itacitinib Adipate
49 Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation Unknown status NCT00774449
50 Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation Unknown status NCT03072849 FAM Therapy

Search NIH Clinical Center for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Genetic Tests for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Anatomical Context for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Organs/tissues related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease:

MalaCards : Lung, Bone Marrow, Bone, Neutrophil, Heart, T Cells, Trachea

Publications for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Articles related to Bronchiolitis Obliterans with Obstructive Pulmonary Disease:

(show top 50) (show all 1089)
# Title Authors PMID Year
1
Mosaic Attenuation Pattern: A Guide to Analysis with HRCT. 62
36202482 2022
2
Ferret Lung Transplantation Models Differential Lymphoid Aggregate Morphology Between Restrictive and Obstructive Forms of Chronic Lung Allograft Dysfunction. 62
35442232 2022
3
Epidemiology, risk factors, and outcomes of lung retransplantation: An analysis of the International Society for Heart and Lung Transplantation Thoracic Transplant Registry. 62
35933297 2022
4
Idiopathic Obliterative Bronchiolitis in a Young Woman: A Rare Case of a Transbronchial Lung Biopsy Contributing to the Diagnosis. 62
35249917 2022
5
The Severity of Functional Small Airway Disease in Military Personnel with Constrictive Bronchiolitis as Measured by Quantitative Computed Tomography. 62
35608541 2022
6
Characterization of Immunopathology and Small Airway Remodeling in Constrictive Bronchiolitis. 62
35550018 2022
7
Iraq/Afghanistan war lung injury reflects burn pits exposure. 62
36038588 2022
8
A rare case of hypereosinophilic obliterative bronchiolitis in an adolescent girl. 62
36045048 2022
9
Severe Airflow Obstruction From Constrictive (Obliterative) Bronchiolitis in Paraneoplastic Autoimmune Multiorgan Syndrome. 62
35257737 2022
10
Constrictive bronchiolitis obliterans with a presumptive etiology of preceding feline herpesvirus infection in a cat. 62
35790990 2022
11
Small airways and airspace inflammation and injury distinguish lung histopathology in deployed military personnel from healthy and diseased lungs. 62
35240130 2022
12
Measurement of Diacetyl and Related Compounds in Coffee Roasteries and Breweries. 62
35051991 2022
13
Identification of a Novel EIF2AK Variant and Genetics-Assisted Approach to Diagnosis of Pulmonary Capillary Hemangiomatosis. 62
35253092 2022
14
Clinical and pathological features of bronchiolitis obliterans requiring lung transplantation in paraneoplastic pemphigus associated with Castleman disease. 62
35060328 2022
15
Sustained Club Cell Injury in Mice Induces Histopathologic Features of Deployment-Related Constrictive Bronchiolitis. 62
34954211 2022
16
A potential mechanism by which aspiration of duodenogastric fluid augments the risk for bronchiolitis obliterans syndrome after lung transplantation. 62
35428458 2022
17
Clinical characteristics of plastic bronchitis in children: a retrospective analysis of 43 cases. 62
35248022 2022
18
Inhibition of Vascular Endothelial Growth Factor Receptors 1 and 2 Attenuates Natural Killer Cell and Innate Immune Responses in an Experimental Model for Obliterative Bronchiolitis. 62
34774518 2022
19
Determinants of Task-Based Exposures to Alpha-Diketones in Coffee Roasting and Packaging Facilities Using a Bayesian Model Averaging Approach. 62
35757620 2022
20
Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A. 62
34864198 2022
21
Case Study: Efficacy of Engineering Controls in Mitigating Diacetyl and 2,3-Pentanedione Emissions During Coffee Grinding. 62
35664098 2022
22
CTOTC-08: A multicenter randomized controlled trial of rituximab induction to reduce antibody development and improve outcomes in pediatric lung transplant recipients. 62
34599540 2022
23
Lymphocytic Airway Inflammation in Lung Allografts. 62
35911676 2022
24
Diffuse cystic lung disease in sickle cell anaemia: a series of 22 cases and a case-control study. 62
34127555 2022
25
Chest pain in a patient with pulmonary arterial hypertension. 62
36062685 2022
26
Obliterative Bronchiolitis as a Systemic Manifestation of Cutaneous Lupus Erythematosus. 62
30601199 2021
27
Effect of CTLA4-Ig on Obliterative Bronchiolitis in a Mouse Intrapulmonary Tracheal Transplantation Model. 62
33980752 2021
28
A follow-up study of post infectious obliterative bronchiolitis in adults and comparative analysis with chronic obstructive pulmonary disease. 62
34747738 2021
29
Inhalational Constrictive Bronchiolitis: The Evolution of our Understanding of this Disease. 62
34415399 2021
30
Pulmonary Pathology Diagnoses in the US Military During the Global War on Terrorism. 62
34363506 2021
31
Protein Signatures of Remodeled Airways in Transplanted Lungs with Bronchiolitis Obliterans Syndrome Obtained Using Laser-Capture Microdissection. 62
34111430 2021
32
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: DIPNECH. 62
33927131 2021
33
A young lady with dyspnoea: Quest for the cause. 62
34284568 2021
34
Overexpression of the MSK1 Kinase in Patients With Chronic Lung Allograft Dysfunction and Its Confirmed Role in a Murine Model. 62
33560725 2021
35
Urgent lung transplantation for thymic neoplasm-associated severe constrictive bronchiolitis with bronchiectasis and radiotherapy-induced organizing pneumonia: A case report. 62
33830653 2021
36
The Usefulness of a Transbronchial Lung Cryobiopsy for Diffuse Bronchiolitis. 62
33281160 2021
37
Putting the spotlight on macrophage-derived cathepsin in the pathophysiology of obliterative bronchiolitis. 62
33985982 2021
38
Microvasculature in murine tracheal allografts after combined therapy with clopidogrel and everolimus. 62
33550369 2021
39
Chronic lung allograft pathology lesions in two rat strain combinations. 62
34164175 2021
40
Native Lung Pulmonary Artery Banding After Single-Lung Transplant for Obliterative Bronchiolitis. 62
32950493 2021
41
miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p. 62
33804639 2021
42
[Fibrotic remodeling of the lung following lung and stem-cell transplantation]. 62
33416936 2021
43
Improvement of constrictive bronchiolitis (bronchiolitis obliterans) after rituximab therapy in 2 patients with primary sjögren syndrome. 62
34401276 2021
44
Case Report: Flavoring-Related Lung Disease in a Coffee Roasting and Packaging Facility Worker With Unique Lung Histopathology Compared With Previously Described Cases of Obliterative Bronchiolitis. 62
34095061 2021
45
Interleukin-18: A Novel Participant in the Occurrence, Development, and Drug Therapy of Obliterative Bronchiolitis Postlung Transplantation. 62
34367377 2021
46
A Strategy for Field Evaluations of Exposures and Respiratory Health of Workers at Small- to Medium-Sized Coffee Facilities. 62
34858915 2021
47
Chronic Lung Disease in Patients With Perinatally Acquired HIV in England: A Retrospective Case-Note Review. 62
32898092 2020
48
Diagnostic Workup of Constrictive Bronchiolitis in the Military Veteran. 62
32761145 2020
49
Constrictive bronchiolitis in diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. 62
33263057 2020
50
Occupational exposures in constrictive bronchiolitis. 62
32825942 2020

Variations for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Expression for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Search GEO for disease gene expression data for Bronchiolitis Obliterans with Obstructive Pulmonary Disease.

Pathways for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

GO Terms for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

Sources for Bronchiolitis Obliterans with Obstructive Pulmonary Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....